BGB-A317-A1217-203
Completed
Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
BeOne Study ID 
BGB-A317-A1217-203
ClinicalTrials.gov ID
EudraCT Number
2020-004658-32
China Drug Trials ID
CTR20213241/CTR20210243
Study Overview
Sex:
All
Age: 18 Years / N/A
Study Documents
Study Protocol Statistical Analysis PlanStudy Overview
Sex:
All
Age: 18 Years / N/A